The New England Journal
Leading Harvard School of Public Health (HSPH) nutrition and health researcher Walter Willett, M.D., Dr. P.H., has written a letter to the President-elect of the American Academy of Family Physicians (AAFP) offering an alternative to the organization's decision, announced in October, to accept a six-figure grant from the Coca-Cola Company to develop web content on beverages and maintaining a healthy lifestyle.
Following one of the largest studies ever conducted in Parkinson's disease (PD), researchers at Mount Sinai School of Medicine report today in The New England Journal of Medicine that rasagiline, a drug currently used to treat the symptoms of PD, may also slow the rate of disease progression.
A substantial percentage of children who get CT scans after apparently minor head trauma do not need them, and as a result are put at increased risk of cancer due to radiation exposure.
BOSTON -- The virus responsible for PML (progressive multifocal leukoencephalopathy), a rare brain disease that typically affects AIDS patients and other individuals with compromised immune systems, has been found to be reactivated in multiple-sclerosis patients being treated with natalizumab (Tysabri).
NEW YORK, September 8, 2009 -- The latest data from groundbreaking human clinical trials of the effectiveness of continuous glucose monitors (CGM) show that the primary determinant of improvements in achieving better diabetes control is regular use of monitors -- six days per week or more -- rather than the age of patients, and that benefits continue well past the time when people with type
Disclosure of financial conflicts of interests to potential participants in research is important, but may have a limited role in managing these conflicts, according to a new study by Johns Hopkins, Duke and Wake Forest.
GAINESVILLE, Fla. -- Scientists have discovered that even in adults born with extremely impaired sight, the brain can rewire itself to recognize sections of the retina that have been restored by gene therapy.
DALLAS -- Aug. 6, 2009 -- The three treatment combinations for clearing the most common form of the hepatitis C virus work equally well with similar side effects, UT Southwestern Medical Center researchers and their colleagues in 13 other institutions have found.
A study of elderly patients receiving CPR in the hospital shows that rates of survival did not improve from 1992 to 2005. During that period, the proportion of hospital deaths preceded by CPR rose, and the proportion of patients who were successfully resuscitated and later discharged home fell.
BOSTON -- Over the past 20 years, the health care system has made tremendous progress in reducing the use of physical restraints among hospitalized elderly patients, a positive change that has had numerous ripple effects, improving outcomes, maintaining mobility and preserving dignity and independence for these individuals.
NEW YORK, NY - MAY 6, 2009 - The Cardiovascular Research Foundation (CRF) announced that its landmark study comparing the safety and efficacy of drug-eluting stents and bare-metal stents was published today in The New England Journal of Medicine.
Brussels, 24 March 2009 --- The current practice of intensively lowering blood glucose in critically ill patients increases the risk of death by 10%. Results of the largest trial of intensive glucose lowering in critically ill patients published today in The New England Journal of Medicine indicate that international clinical guidelines need urgent review.
Many popular diets emphasize either carbohydrate, protein or fat as the best way to lose weight. However, there have been few studies lasting more than a year that evaluate the effect on weight loss of diets with different compositions of those nutrients.
In a small, initial clinical trial led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, doctors found that up to 75 percent of people with Crohn's disease responded to an experimental new treatment, and up to 50 percent had long-term remission of symptoms.
An international study led by a Canadian researcher shows that men with advanced, incurable prostate cancer can survive an average of three months longer and face less symptoms when offered a new treatment for prostate cancer.
Published in tomorrow's issue of The New England Journal of Medicine, the study involved 24 countries and over two years tracked more than 1,000 patients with advanced hormone-refractory prostate cancer. Researchers looked at several outcome measures -- survival, pain relief, improved quality of life, and the amount of PSA in the patients' blood, which indicates the amount of cancer present in the body. In all these measures, men who received docetaxel administered every three weeks did better than those who received mitoxantrone, and it improved survival by an average of three months.
